The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.
about
Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjectsPharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin.Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
P2860
The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
The need for multiple doses of ...... o drug-drug interaction study.
@en
The need for multiple doses of ...... o drug-drug interaction study.
@nl
type
label
The need for multiple doses of ...... o drug-drug interaction study.
@en
The need for multiple doses of ...... o drug-drug interaction study.
@nl
prefLabel
The need for multiple doses of ...... o drug-drug interaction study.
@en
The need for multiple doses of ...... o drug-drug interaction study.
@nl
P2860
P356
P1476
The need for multiple doses of ...... vo drug-drug interaction study
@en
P2093
Ya-Chi Chen
P2860
P304
368-9; author reply 370
P356
10.1177/0091270008325931
P50
P577
2009-03-01T00:00:00Z